The neural stem cell secretome and its role in brain repair. by Willis, Cory et al.
Contents lists available at ScienceDirect
Brain Research
journal homepage: www.elsevier.com/locate/brainres
Review
The neural stem cell secretome and its role in brain repair
Cory M. Willis⁎, Alexandra M. Nicaise, Luca Peruzzotti-Jametti, Stefano Pluchino
Department of Clinical Neurosciences and NIHR Biomedical Research Centre, University of Cambridge, Hills Road, CB2 0HA Cambridge, UK
H I G H L I G H T S
• Transplantation of human NSCs has shown beneﬁcial eﬀects in rodent models of neurodegenerative diseases.
• The secretome of human NSCs plays a pivotal role in promoting neuroprotection and regeneration.
• Human NSC-derived extracellular vesicles as a promising candidate therapy.
• Clinical trials have found human NSC transplantation to be safe and well-tolerated.
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A B S T R A C T
Compelling evidence from experimental animal disease models and early-phase clinical trials identiﬁes the
transplantation of neural progenitor/stem cells (NSCs) as a viable path towards the development of clinically
applicable exogenous stem cell therapies.
Building from current advances in the ﬁeld of NSC biology and following the positive outcomes of NSC
transplantation studies, the contemporary view is that transplanted NSCs act as local ‘factories’ capable of
producing and secreting a wide array of immune and neurotrophic factors. This has launched a ‘stem cell race’ to
identify the mechanisms behind stem-cell mediated repair in what has been labeled the paracrine hypothesis. This
hypothesis proposes that NSC grafts act as a natural source of potent biologics capable of modulating and
promoting the restoration of several key functions in the central nervous system (CNS) tissue following acute or
chronic tissue damage.
Investigators have been inspired to examine novel ways to harness and utilize the pro-regenerative properties
of NSC therapies as an alternative approach to a more classical (small molecule based) treatment of CNS dis-
eases.
In this review, we will discuss the most recent ﬁndings of human NSC (hNSCs) transplants in experimental
animal models of CNS diseases that identify of hNSC-secreted factors, including those traﬃcked within extra-
cellular membrane vesicles (EVs), and the outcomes of recent clinical trials utilizing hNSC therapeutics in CNS
diseases.
1. Introduction
A growing body of literature into understanding and dissecting the
biology of NSCs has elucidated a wide array of beneﬁcial properties of
these cells. This has led to major strides in the ﬁeld in harnessing their
restorative, regenerative, and protective potential for the development
of pre-clinical therapies in the treatment of many common and devas-
tating neurodegenerative diseases, such as: spinal cord injury (SCI),
Parkinson’s disease (PD) (Redmond et al., 2007; Han et al., 2015;
L'Episcopo et al., 2018), Alzheimer’s disease (AD) (Duncan and
Valenzuela, 2017), multiple sclerosis (MS) (Pluchino et al., 2003;
Pluchino and Martino, 2008; Pluchino et al., 2009; Peruzzotti-Jametti
et al., 2018; Volpe et al., 2019), amyotrophic lateral sclerosis (ALS)
(Glass et al., 2012), and stroke (Bacigaluppi et al., 2008; Lee et al.,
2008; Hermann et al., 2014; Bacigaluppi et al., 2016; Bernstock et al.,
2019). Despite historical attempts to utilize stem cell transplants as
therapies in diseases of the CNS, recent literature has suggested that the
eﬀects orchestrated by NSC transplants is not limited to the de novo
generation of graft-derived neurons and glial cells (Martino and
Pluchino, 2006; Martino et al., 2011; Boese et al., 2018). Data has in
fact led investigators to re-think the use of whole-cell transplants to
derive beneﬁt. Rather, the introduction of factors produced by neural
stem cells has been found to provide a supportive milieu that allows
injured cells to resist further degeneration, promote repair, drive
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regeneration of injured tissue, and decrease inﬂammation (Table 1)
(Drago et al., 2013; Doeppner et al., 2017; Yang et al., 2018).
The classical view that NSC grafts only function through structural
cell replacement has been recalibrated over the past decade with re-
search demonstrating their capabilities to sense diverse signals, migrate
to speciﬁc biological niches, and execute complex behaviors (Pluchino
et al., 2010). NSCs are being extensively investigated for their capacity
to signal to the endogenous host cells upon transplantation, reduce
chronic inﬂammation and promote regeneration in experimental CNS
diseases (Martino and Pluchino, 2006). Following NSC transplantation,
sustained graft-to-host exchanges of signals has led to trophic eﬀects on
endogenous brain cells and beneﬁcial modulatory actions on innate and
adaptive immune responses that have ultimately promoted the healing
of the injured CNS (Fig. 1) (Pluchino and Martino, 2008; Pluchino et al.,
2010; Pluchino et al., 2005; Serra et al., 2008; Pluchino et al., 2009;
Cossetti et al., 2012; Pluchino and Cossetti, 2013; Cossetti et al., 2014).
Considerable eﬀorts are currently underway to develop, standar-
dize, and assess the safety of autologous hNSC transplantation as a
therapy for many chronic CNS diseases, with a small group of clinical
trials at diﬀering stages of progression (Table 2). As an alternative
approach, the use of stem cell secreted factors for the development of
treatments is receiving signiﬁcant attention from investigators. Active
exploration is underway way to reﬁne technologies for use in exploiting
stem cell secreted factors in the development of treatments using these
naturally produced biologics. This has required the extensive applica-
tion of analytical techniques such as targeted/untargeted proteomics
and metabolomics to identify potential novel therapeutic factors from
the NSC secretome (Table 1) (Drago et al., 2016; Shoemaker and
Kornblum, 2016; Iraci et al., 2017). Analytical technologies coupled
with the use of gene expression approaches to develop modiﬁed NSCs
capable of actively releasing discrete levels of speciﬁc beneﬁcial factors
is an area of intensive investigation. For example, this review will
highlight papers that use genetically-engineered hNSCs to secrete an
increase of beneﬁcial factors, such as IGF-1 (insulin-like growth factor
1), in rodent models of neurodegenerative disease (Park et al., 2013;
McGinley et al., 2016). Finally, the development of cell-free (or acel-
lular) therapeutics that use hNSC-derived biologics, instead of whole,
allogeneic NSCs, has emerged as a concept in regenerative medicine to
provide beneﬁcial eﬀects via modulation of the function of tissue-re-
sident CNS cells.
In this review, we will outline the most current literature regarding
human NSC transplantation in animal models of neurodegenerative
diseases and how their secretome promotes regeneration, neuropro-
tection, and dampens inﬂammation. We will also discuss the outcomes
of completed early clinical trials of hNSC transplants in human patients
and discuss the growing ﬁeld of acellular therapeutics utilizing the NSC
secretome.
2. NSC transplantation in neurodegenerative disorders
NSCs are self-renewing, multi-potent cells characterized by their
capacity to diﬀerentiate into multiple cell types, including astrocytes,
oligodendrocytes, and neurons, making them an ideal therapeutic
candidate for neurodegenerative disorders. In mammalian embryonic
development these cells give rise to neurons and glia, and during
adulthood have been found to persist as small populations within the
subventricular zone (SVZ) near the lateral ventricles and in the sub-
granular zone (SGZ) of the hippocampus (Ma et al., 2009). Rodent NSCs
(rNSCs) can be extracted directly from neural tissue, such as the neu-
roectoderm in the developing fetus, and from the SVZ or SGZ in post-
natal and adult tissue (Lee et al., 2008). These NSCs can then be pro-
pagated in vitro for eventual transplantation in rodent disease models.
The initial success of transplantation studies in laboratory research
is largely attributed to the immunological compatibility between the
donor cells and the host (Tullis et al., 2014). Allografts, where the
transplanted cells and the host are not genetically identical, but mem-
bers of the same species is most commonly performed in the lab, which
would include rodent NSCs into rodents.
This review will outline primarily xenografts, where donor tissue
will be from a diﬀerent species compared to the host (ie. human cells
into rodents). On the other hand, autographs are transplants where the
transplanted, autologous, tissue comes from the host, which is the most
ideal in human transplants. Diﬀerences in major histocompatibility
complex (MHC) antigens, in humans known as the human leukocyte
Table 1
Main growth factors detected in the hNSC-derived secretome.
Genes
Gene ID Gene Name Disorder Technique Condition Reference
VEGF Vascular endothelial growth factor Ischemic Stroke qPCR in vitro (Hicks et al., 2013)
VEGF, Vegf ALS qPCR in vivo (Kondo et al., 2014)
GDNF Glial cell line-derived neurotrophic factor SCI qPCR in vivo (Romanyuk et al., 2015)
Gdnf ALS qPCR in vivo (Kondo et al., 2014)
Nt3 Neurotrophin-3 ALS qPCR in vivo (Kondo et al., 2014)
BFGF Basic ﬁbroblast growth factor Ischemic stroke qPCR in vitro (Hicks et al., 2013)
EGF Epidermal growth factor Ischemic stroke qPCR in vitro (Hicks et al., 2013)
NGF Nerve growth factor SCI qPCR in vivo (Romanyuk et al., 2015)
FGF8 Fibroblast growth factor 8 SCI qPCR in vivo (Romanyuk et al., 2015)
Proteins
Protein ID Protein Name Disorder Technique Condition Reference
BDNF Brain-derived neurotrophic factor Ischemic stroke IF in vivo (Huang et al., 2014)
Alzheimer’s disease WB in vivo Park et al., 2013; (Lee et al., 2015)
Parkinson’s disease LC-MS/MS in vitro (Mendes-Pinheiro et al., 2018)
VEGF Vascular endothelial growth factor Ischemic stroke WB, ELISA in vitro (Hicks et al., 2013)
Alzheimer’s disease WB in vivo (Lee et al., 2015)
GDNF Glial cell line-derived neurotrophic factor Parkinson’s disease LC-MS/MS in vitro (Mendes-Pinheiro et al., 2018)
NGF Nerve growth factor Alzheimer’s disease WB in vivo Park et al., 2013; (Lee et al., 2015)
BFGF Basic ﬁbroblast growth factor Ischemic stroke WB, ELISA in vitro (Hicks et al., 2013)
EGF Epidermal growth factor Ischemic stroke WB, ELISA in vitro (Hicks et al., 2013)
IGF-1 Insulin-like growth factor Alzheimer’s disease WB, ELISA, IF in vitro (McGinley et al., 2016)
Abbreviations: qPCR, quantitative polymerase chain reaction; ALS, amyotrophic lateral sclerosis; SCI, spinal cord injury; IF, immunoﬂuorescence; WB, western blot;
ELISA, enzyme-linked immunosorbent assay; LC-MS/MS, liquid chromatography with tandem mass spectrometry.
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antigen (HLA), determines the successful integration of the transplant.
If the donor and the recipient are suﬃciently matched in the MHC re-
gion and immune suppression is used transplants are generally suc-
cessful (Tullis et al., 2014). When not matched, and no im-
munosuppressants are given, the transplant will be deemed foreign by
the host and rejected by the adaptive human system, which then in-
itiates an immune response to remove foreign pathogens. In the case of
CNS transplants this reaction would be extremely debilitating if not
fatal, therefore human clinical trials have proceeded with caution.
Many initial studies of transplantation in neurodegenerative disease
models have been performed using rodent cells into rodent hosts, but
this review will focus on human NSC transplants into rodent models of
disease. This is important to test how grafted human cells react in vivo
in a disease model. Furthermore, there are a wealth of animal models,
including transgenic mice, which have been generated that closely
mimic the pathological and behavioral deﬁcits that are associated with
neurodegenerative diseases, and therefore are ideal models to test
human NSCs.
Human NSCs can be derived in the same ways as rodent NSCs, in-
cluding from fetal/embryonic tissue, postmortem adult tissue, and more
recently from the derivation of induced pluripotent stem cells (iPSC)
and directed stem cell technology (Thier et al., 2012). Many of the
studies reviewed utilize hNSCs generated from fetal tissue, which raises
ethical concerns about tissue source and genetic stability if these cells
have been maintained long term in culture.
The advent of iPSC technology has enabled diﬀerentiated NSCs to
bypass potential immunogenicity issues associated with transplanta-
tion, and circumvent the ethical issues associated with the use of fetal
tissue. A limitation of fetal cell transplantation is the small amount of
tissue available, which does not meet the current needs of patients with
neurodegenerative diseases. NSCs derived from fetal tissue can be ex-
panded, but research suggests that their expandability is limited, which
raises concern on their genetic stability over multiple passages (Signer
and Morrison, 2013). Nevertheless, NSCs derived from iPSCs still raise
concerns due to their potential tumorigenic nature. Several groups have
reported teratoma formation following the transplantation of iPSC-de-
rived cells, and even de novo mutations in mitochondrial DNA which
produce immunogenic neoepitopes (Duinsbergen et al., 2009;
Seminatore et al., 2010; Nori et al., 2015; Deuse et al., 2019). Even if
attempts to remove undiﬀerentiated iPSCs from diﬀerentiated NSCs are
successful, the risk of tumor formation is not completely eliminated and
caution needs to be taken (Itakura et al., 2017). Furthermore, graft
rejection is still a major unresolved issue in the ﬁeld (Simonson et al.,
2015). Despite major advances in stem cell biology, the ﬁeld has not yet
overcome this hurdle. Findings from pre-clinical animal models have
revealed a critical need to utilize genetically immunodeﬁcient mice
and/or a strict regimen of immunosuppressive therapy in parallel to
stem cell transplants to ensure graft survival (Swijnenburg et al., 2008;
Pomeshchik et al., 2015). Therefore, extensive pre-clinical studies must
be performed to ensure good manufacturing practices (GMP) are es-
tablished and upheld to ensure long-lasting transplant survival and
limited graft rejection in the clinical setting. Lastly, it is important that
transplanted cells possess an intact and stable genome, however it is
currently unknown how iPSC reprogramming aﬀects genomic and
epigenomic stability. Some research has suggested that long-term ex-
pansion of cells and cellular reprogramming can alter the genetic sta-
bility and introduce dangerous genetic aberrations in the cells (Zhang
et al., 2018). It is therefore important to continue research on opti-
mizing cellular reprogramming and establishing standards to check for
genomic integrity before clinical applications. New technology within
the past couple of years has been developed which generates directly
induced NSCs from ﬁbroblasts, bypassing the iPSC stage, named in-
duced NSCs (iNSCs) (Thier et al., 2012). These cells therefore avoid the
ethical implications associated with using fetal tissue and eliminate the
pluripotent tumorigenic state. Current work has deemed rodent iNSCs
to be safe when transplanted into a mouse model of MS, and promote
anti-inﬂammatory activity (Peruzzotti-Jametti et al., 2018). Future
work is being carried out on human iNSCs to determine their safety and
Fig. 1. The observed exogenous hNSC secretome in rodent models of neurodegenerative disease. Up arrow (↑) indicates an increase; down arrow (↓) indicates a
decrease.
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tolerability in mice.
2.1. Spinal cord injury
Decades of spinal cord injury (SCI) research has made it abundantly
clear that the ability to design treatments that induce long-distance
regeneration of injured axons to improve function has remained elu-
sive. This development is hampered on two fronts: by the limited re-
generative capabilities of nervous tissue and the inability to replace lost
and injured neurons. However, accumulated evidence from explorative
studies of rodent NSC transplants into rodent SCI models have shown
tremendous therapeutic beneﬁt via neurotrophic growth factor pro-
duction and secretion promoting axonal regeneration, modulating the
immune response, and preserving host tissue (Ogawa et al., 2002; Teng
et al., 2002; Lu et al., 2003; Ziv et al., 2006; Cusimano et al., 2012;
Hawryluk et al., 2012). This has led to the investigation of whether
human NSC xenografts are also capable of beneﬁcial growth factor
production and secretion in pre-clinical SCI animal models as a pro-
mising next step in the development of NSC based therapies for human
beneﬁt (Iwanami et al., 2005; Yamane et al., 2010).
Recent studies have investigated the beneﬁcial eﬀect of xeno-
transplantation of hNSCs in a rat compression injury model of SCI,
which causes inﬂammation and some neuronal death (Amemori et al.,
2015; Romanyuk et al., 2015; Ruzicka et al., 2017; Karova et al., 2019).
In one study, human induced pluripotent stem cell-derived NSCs
(hiPSC-NSCs) (5 × 105 cells) were transplanted into the injury epi-
center one week following SCI and animals were observed for up to
17 weeks. Remarkably, animals displayed a rapid and signiﬁcant motor
improvement as early as two weeks after hiPSC-NSC transplantation,
reaching a plateau at eight weeks post-transplantation with sustained
beneﬁt until the end of the observation period. In contrast, rats re-
ceiving saline injections exhibited minimal functional recovery beyond
the spontaneous recovery typically observed in this SCI model. Mor-
phometric evaluation of the spinal cord grey and white matter revealed
a robust sparing of tissue in hiPSC-NSCs transplanted rats, with a sig-
niﬁcant increase in tissue volume observed two months after SCI
(Romanyuk et al., 2015). In wanting to determine the source of neu-
rotrophin production (i.e., endogenous vs. exogenous), gene expression
analysis of rat and human brain derived neurotrophic factor (Bdnf),
vascular endothelial growth factor (Vegf), nerve growth factor (Ngf),
neurotrophin-3 (Nt3), ﬁbroblast growth factor 8 (Fgf8), and glial cell
line-derived neurotrophic factor (Gdnf) were assessed at eight weeks
post-transplantation in injured host tissue. These speciﬁc neurotrophins
were proﬁled due to their known roles in promoting neuronal and glial
maturation (Habtemariam, 2018). Surprisingly, gene expression of rat
neurotrophins did not change following hiPSC-NSC transplantation,
rather the human genes NGF, FGF8, and GDNF were signiﬁcantly up-
regulated in the host tissue compared to mRNA levels of pre-diﬀer-
entiated hiPSCs (Fig. 1, Table 1) (Romanyuk et al., 2015). The results
from this study suggest that transplantation of hNSCs does not inﬂuence
the expression of host/endogenous neurotrophins in the injured rat
spinal cord. Rather, the evidence points towards exogenous hNSCs as
capable of long-term graft survival and maintaining an active gene
expression proﬁle for neurotrophin production to provide a permissive
environment for both exogenous and endogenous axonal sprouting and
functional recovery following SCI.
In a follow-up study by Amemori et al., rats with a compression
induced SCI in the thoracic region were given an intrathecal injection of
hiPSC-NSCs (5 × 105 cells) at a site distal (caudal) to the lesion epi-
center one week following the injury (Amemori et al., 2015). Moderate
functional improvements were observed in rats receiving intrathecal
xenografts. However intrathecal hiPSC-NSCs had poor long-term sur-
vival being undetectable at the site of administration or in the spinal
cord tissue. Further, while improvements of white matter sparing and
increased axonal sprouting were observed in these animals, endogenous
and exogenous expression of neurotrophic growth factors was absent
(Amemori et al., 2015). Thus, despite moderate therapeutic beneﬁt of
intrathecally transplanted hiPSC-NSC, the absence of long-term en-
graftment and survival has revealed a critical need to identify the op-
timal route and site of administration.
Transplanted rNSCs have been shown to possess potent immune
regulatory properties in vivo after transplantation into an animal model
of SCI (Cusimano et al., 2012). To determine if hNSCs have similar
immunomodulatory capabilities, Ruzicka et al. compared NSCs derived
from hiPSCs or an immortalized spinal fetal line (SPC-01) in a pre-
clinical compression induced SCI model in rats (Ruzicka et al., 2017).
One week following SCI, hiPSC-NSCs (5 × 105 cells) or SPC-01
(5 × 105 cells) were transplanted intralesionally. Both cell types
showed high survival at two months post-engraftment and resulted in
improved functional recovery, while only the hiPSC-NSC treated ani-
mals had signiﬁcant white matter sparing. Further, both hiPSC-NSC and
SPC-01 transplants resulted in reduced astrogliosis surrounding the
central lesion area as evidenced by a smaller GFAP± volume. On the
other hand, only hiPSC-NSC treated spinal cords showed a down-
regulation of CD86 and CD163, markers of M1 (pro-inﬂammatory) and
M2 (anti-inﬂammatory) macrophages, respectively, highlighting the
potential of transplanted hNSCs to modulate reactive astrocytes and
microglia within the lesioned microenvironment. Analysis of cytokine
and chemokine expression from lesioned spinal cord tissue following
transplanted hiPSC-NSCs and SPC-01 s revealed a decrease in pro-in-
ﬂammatory cytokines TNF-α (Ousman and David, 2001), IL-1β (Eskan
et al., 2008), and IL-2 (de Rham et al., 2007) and chemokines MIP-1α
(Ousman and David, 2001) and CCL5 (i.e. RANTES) (Lin et al., 2011)
and an increase in anti-inﬂammatory factors IL-4 (Fenn et al., 2014)
and IL-12p70 (Yaguchi et al., 2008) (Fig. 1). This suggests the im-
munomodulatory potential of hiPSC-NSC and SPC-01 xenografts in
shaping the lesion microenvironment towards a more permissive state
for regeneration of damaged tissue.
Further investigation into the immunomodulatory eﬀect of trans-
planted NSCs focused on the NF-κB pathway (Karova et al., 2019). NF-
κB is an inducible transcription factor that mediates immune and in-
ﬂammatory responses (Pizzi et al., 2002) and inhibition of this pathway
has been shown to improve functional recovery after SCI (Brambilla
et al., 2005). Rats were subjected to a compression-induced SCI and one
week after injury SPC-01 s (5 × 105 cells) were transplanted in-
tralesionally. A signiﬁcant reduction in both TNF-α production and
nuclear translocation of NF-κB was observed in the rats receiving
transplants (Karova et al., 2019). This resulted in increased tissue
sparing and reductions in astrogliosis, a cell type known to have in-
creased NF-κB activation in SCI (Brambilla et al., 2005). This was at-
tributed to a paracrine eﬀect of transplanted SPC-01 s in modulating the
immune response, however no further proﬁling of the transplanted cells
secretome was performed to provide conclusive evidence.
All of these studies point to potentially important interactions be-
tween transplanted hNSCs and the lesion environment to reconﬁgure
the deleterious inﬂammatory state to protect and promote tissue re-
generation (Fig. 1). However, there is a severe lack of mechanistic
ﬁndings of immune modulation following human xenografts in rodent
models of disease, in part due to the heavy use of immunodeﬁcient
animals to assess functional and molecular outcomes. In fact, studies
rely almost exclusively on superﬁcial, indirect correlative cause and
eﬀect relationships to establish an immunomodulatory role for trans-
planted cells. Another caveat that is poorly addressed in the ﬁeld is the
potential for opportunistic infections directed at the human xenografts.
As current pre-clinical models rely on immunodeﬁcient or im-
munosuppressed (immune competent) animals living in ultra-clean
environments, the risk of infection is rare. Therefore, future studies are
warranted to assess these questions to provide a more While the de-
scribed ﬁndings of transplanted hNSCs in SCI are promising and hold
great potential for their use as an adjunctive therapy, a more intense
and deeper investigation into the mechanisms driving these cells is
needed to make this potential become a reality.
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2.2. Ischemic stroke
The global burden of stroke is immense, being the second leading
cause of death and major disability worldwide (Mozaﬀarian et al.,
2016), with rising incidence rates due to an ever-increasing aged po-
pulation (Sander et al., 2015). Despite intensive eﬀorts to develop
treatments for improved post-stroke care, eﬀective treatments are
limited and do little to address post-stroke injury, which leads to ex-
tensive CNS damage, including inﬂammation, erosion of blood–brain-
barrier (BBB) integrity, neuronal death, and substantial loss of tissue
volume (Lipton, 1999; White et al., 2000; Mena et al., 2004; Besancon
et al., 2008; Kulik et al., 2008; Iadecola and Anrather, 2011; Petrovic-
Djergovic et al., 2016). Thus, to develop fully applicable and eﬀective
therapeutic strategies for the regeneration of post-stroke ischemic
tissue, therapies must be designed to interact with and modulate mul-
tiple mechanisms of action to target multiple pathways. Previous at-
tention has focused on the identiﬁcation of targets to promote neuro-
genesis from endogenous NSCs, however it is now known the
endogenous pool of NSCs is not capable of supplying enough cells to
meet the demands required for the repair of neurological damage
(Arvidsson et al., 2002; Kokaia and Lindvall, 2003; Thored et al., 2006;
Pluchino et al., 2008). Therefore, the supplemental engraftment of
exogenous hNSCs into the post-stroke brain is an attractive option to
provide immunomodulatory, neurotrophic, and reparative support
(Boese et al., 2018; Hicks et al., 2013; Huang et al., 2014; Eckert et al.,
2015; Ryu et al., 2016; Bernstock et al., 2017; Lee et al., 2017).
The middle cerebral artery occlusion model (MCAO) is a thoroughly
validated pre-clinical model of ischemic stroke that is extensively used
to investigate the post-stroke brain (Canazza et al., 2014). Utilizing this
model, Huang et al. transplanted human fetal NSCs (1 × 105 cells) into
the mouse hippocampus 24 h following MCAO to determine the po-
tential beneﬁt on post-stroke outcomes (Huang et al., 2014). Mice re-
ceiving hNSC transplants showed rapid, signiﬁcant improvements in
behavioral outcomes, most notably within the ﬁrst week post-trans-
plantation. Improved behavioral outcomes were concomitant with re-
ductions in infarct volume and BBB damage (Huang et al., 2014). A
signiﬁcant increase in the production of BDNF, a major neurotrophin
known to promote functional recovery and neuroprotection after stroke
(Emanueli et al., 2003), was also observed in the lesioned cortex in
hNSC transplanted animals compared to non-transplanted, suggesting
that the tissue preservation eﬀects of transplanted hNSCs works
through stimulating BDNF secretion. Tissue preservation was also at-
tributed, in part, to signiﬁcant reductions in the expression of pro-in-
ﬂammatory cytokines Tnf-α, Il-6, and Il-1β, cell adhesion molecules
ICAM-1 and VCAM-1, and chemokines Mcp-1 and Mip-1α, as well as
dampened inﬂammation and microglia/macrophage activation, sug-
gestive of an immunomodulatory eﬀect of hNSC transplants in post-
stroke recovery (Fig. 1). A follow-up study from the same team using
hiPSC-NSC transplants (1 × 105 cells) 24 h following MCAO in mice
identiﬁed a similar immunomodulatory and neurotrophic proﬁle
(Huang et al., 2014; Eckert et al., 2015). As well, decreased levels of IgG
and matrix metalloproteinase (MMP) activity was observed in rodents
receiving hNSCs (Eckert et al., 2015). The presence of parenchymal IgG
and increased MMP activity is associated with the dysfunction of tight
junctions between endothelial cells that comprise the BBB, which sug-
gests improved BBB integrity following hNSC transplantation (Yang
et al., 2007; Chen et al., 2009).
Additional studies using the MCAO model in rats has provided
further evidence of a potent paracrine eﬀect of transplanted hNSCs. For
example, Lee et al. found that delayed transplantation (7 days post-
stroke) of hiPSC-NSCs (1 × 106 cells) into post-stroke rats resulted in
signiﬁcantly lower amounts of Iba-1± and ED1+ microglia cells, re-
duced expression of glial ﬁbrillary acidic protein (GFAP) positive as-
trocytes, and increased angiogenesis (Lee et al., 2017). Enhanced an-
giogenesis seems to be a common eﬀect of transplanted hNSCs (Hicks
et al., 2013; Ryu et al., 2016; Lee et al., 2017). A similar study also
identiﬁed increased angiogenesis in a rat MCAO model following
transplantation of hNSCs (4.5 × 105 cells), which was attributed to the
increased production and secretion of pro-angiogenic factors VEGF,
basic ﬁbroblast growth factor (bFGF), and epidermal growth factor
(EGF) as evidenced by in vitro biochemical analysis (Fig. 1, Table 1)
(Hicks et al., 2013). Transplanted hNSCs have also been suggested to
inﬂuence the proliferation and diﬀerentiation of endogenous NSCs. Ryu
et al. found that hNSCs (6 × 105 cells) transplanted 24 h post-stroke
into rats were capable of stimulating the proliferation of endogenous
rNSCs in the subventricular zone and dentate gyrus of the ischemic
hemisphere. Further, enhanced diﬀerentiation of endogenous rNSCs
into neurons and GFAP+ astrocytes within these regions was also ob-
served (Ryu et al., 2016). Surprisingly, there was a complete absence of
hNSCs observed within these regions using human nuclear antigen
staining, indicating that transplanted hNSCs did not migrate to these
brain regions. This suggests that hNSCs acted through a paracrine
fashion to promote proliferation.
2.3. Alzheimer’s disease
There are approximately 50 million people living with dementia
resulting in an estimated global cost of care upwards of US$818 billion.
However, due to national demographics identifying a rapidly aging
global population, the number of people with dementia is anticipated to
rise to 132 million by 2050 (Alzheimer's disease facts and ﬁgures, 2015;
Alzheimer's disease facts and ﬁgures, 2016). Alzheimer’s disease (AD) is
the most commonly associated pathology with dementia and has been
the focus of intense investigative eﬀorts to develop clinically useful
therapies to combat the signiﬁcant social, economic, and medical im-
pacts of this disease. As mentioned previously, the use of exogenous
hNSC-based therapies to restore degenerated neuronal networks has
seen success in SCI and stroke, with similar studies occurring in rodent
models of aging and AD (Duncan and Valenzuela, 2017). For example,
hNSCs genetically engineered to over-express choline acetyltransferase
(ChAT) and transplanted into aged mice improved their cognitive
function and physical activity (Park et al., 2013). Park and colleagues
used an immortalized NSC line that were previously developed from a
15-week old human fetus and infected the cells with a retrovirus to
induce over-expression of the human ChAT gene. In AD patients de-
creased activity of ChAT is observed, which is responsible in acet-
ylcholine (ACh) synthesis (Terry and Buccafusco, 2003). This is asso-
ciated with the dysfunction of the presynaptic cholinergic system,
therefore causing cognitive deﬁcits (Coyle et al., 1983). Enhancing ACh
concentration in AD is a goal of many treatments (Terry and
Buccafusco, 2003), as a result modifying hNSCs to over-express ChAT
and transplanting these cells may be a viable therapeutic.
Aged (18 months) wild type outbred ICR mice received 4 × 105
hNSCs-ChAT via intracerebroventricular injection without im-
munosuppression. Aged animals (18 months) typically show severe
impairment in learning and memory function, but 4 weeks after
transplant demonstrated signiﬁcant improvement in behavioral and
cognitive functions compared to their aged counterparts. 5 weeks after
transplantation there was a signiﬁcant increase in ACh concentration
and the transplanted cells were found to diﬀerentiate into neurons and
astrocytes. This was associated with higher levels of BDNF and NGF in
the aged animals, along with increases in cholinergic system genes,
which are normally down regulated in aged animals. This study de-
monstrates how genetically engineering the secretome of hNSCs can aid
in the restoration of age-related changes, but also provide an increase in
neuroprotective factors such as BDNF and NGF. However, the long-term
eﬀects, including if the increase in ACh is long term, of the transplanted
genetically engineered hNSCs are unknown.
Another example is a study which used human cortical NSC lines,
derived from fetal tissue, and transfected the cells with a lentiviral
vector to induce expression of insulin-like growth factor-1 (IGF-1)
(McGinley et al., 2016). IGF-1 is a trophic factor that is essential for
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neural development and function and exerts neuroprotective eﬀects on
neurons (Russo et al., 2005). Reduced levels have been associated with
cognitive decline (Miltiadous et al., 2011). In vitro experiments assaying
amyloid-β toxicity in neurons co-cultured with the IGF-1 hNSCs using
trans-well inserts revealed a neuroprotective paracrine mechanism
compared to non-modiﬁed hNSCs co-culture and no co-culture
(McGinley et al., 2016).
The double transgenic AD mouse model, APP/PS1, which expresses
a chimeric mouse/human amyloid precursor protein (APP) and a mu-
tant human presenilin (PS1) protein was used. These mutations are
associated with early-onset AD and cause AD-like pathology in mice. At
11 weeks of age mice were given bilateral injections into the hippo-
campus at 3 sites, injecting a total of 180,000 cells, accompanied with
immunosuppressive treatment using tacrolimus. 10 weeks post-trans-
plantation the grafted cells were found in the hippocampal region of the
AD mice and were diﬀerentiated into neurons (McGinley et al., 2016).
The study did not further investigate if the transplantation improved
behavior or AD pathology in the mice but provided feasibility that the
genetically modiﬁed human cells are safe when transplanted into ro-
dents and can integrate and diﬀerentiate after 10 weeks. Further work
is needed to understand how the transplanted hNSC-IGF-1 integrate
within the AD-like environment and how their elevated secretion of
IGF-1 can potentially provide neuroprotection.
Lastly, Lee et al. transplanted human NSCs derived from fetal tissue
into the transgenic NSE/APPsw AD mouse model, which carries the
mutated human APP gene (Lee et al., 2015). hNSCs were injected
(1x105) bilaterally into the lateral ventricles, and mice received im-
munosuppression (cyclosporine A). 5 weeks after transplantation the
mice had improved spatial memory and demonstrated a decrease in tau
phosphorylation, Aβ42 levels, and gliosis, which are all highly upre-
gulated in this AD mouse model (Lee et al., 2015). 7 weeks after
transplantation the hNSCs engrafted, migrated widely from the trans-
plantation site, and diﬀerentiated mostly towards immature neurons. In
vitro work demonstrated that the hNSCs secreted trophic factors, in-
cluding BDNF, NGF, and VEGF, and in parallel these factors were found
increased in the transplanted mice and believed to be associated with
the decrease in tau phosphorylation (Fig. 1). In addition, human neu-
roblastoma cells expressing the mutated APP gene treated with hNSC
CM decreased the production of Aβ. Moreover, co-culturing hNSCs with
inﬂammatory microglia in a transwell system decreased inﬂammation
through the secretion of anti-inﬂammatory factors (TGFβ1, IL4, IL13).
Nevertheless, exactly what factors are involved in attenuating the glial
responses in the AD mice with transplants is unknown. Overall, this
study implicates the regenerative and protective eﬀect of the hNSC
secretome in vitro as well as in vivo and provides proof of principle that
these cells can be transplanted safely in rodents and migrate and in-
tegrate within the CNS (Lee et al., 2015).
The complete molecular mechanisms that mediate the positive ef-
fects described in aged as well as AD-like mice with hNSC transplants
have not yet been fully realized, but the likely cause is the paracrine
release of neurotrophic factors, such as BDNF, NGF, and VEGF (Table 1)
(McGinley et al., 2016; Lee et al., 2015), which further supports a
beneﬁcial eﬀect of transplanted hNSCs in AD (Fig. 1). Additionally,
more work to understand the factors within the hNSC secretome that
provide the greatest beneﬁt for dementia and AD pathology can be
harnessed through genetic-engineering to exploit the natural processes.
2.4. Parkinson’s disease
Parkinson’s disease (PD) is the second most common neurodegen-
erative disease aﬀecting adults after AD (de Rijk et al., 2000). PD is
associated with both motor and non-motor dysfunction and involves the
substantial loss of dopaminergic neurons (DA) in the substantia nigra
throughout the course of the disease (Cheng et al., 2010). Despite PD
patients having access to established therapeutic approaches, such as
drug treatment (L-DOPA) (Fahn et al., 2004) and deep-brain
stimulation (Limousin et al., 1995), PD is an incurable disease and these
treatment strategies only temporarily alleviate the associated clinical
symptoms. Theoretically, replacing DA neurons in the striatum using
fetal grafts could oﬀer a cure for these patients, but these trials have
faced diﬃculties. Tissue from human fetal ventral mesencephalon
(FVM) has been used a source of DA cells grafted into patients. Re-
markably these cells were shown to promote clinical beneﬁts in these
patients, and at postmortem were shown to integrate and survive for
decades (Wenning et al., 1997; Hallett et al., 2014; Li et al., 2016).
However, there was a high incidence of graft-induced dyskinesia re-
ported, attributed to the presence of serotoninergic neurons within the
transplant (Politis et al., 2011). In addition, in both a rat PD model
(fetal rat tissue transplanted into rats with PD injury) and in patients
grafted with fetal tissue it was shown that a host-to-graft transfer of
disease can occur. In rats it was found that the grafted cells can take up
host-derived α-synuclein, express the protein which can then aggregate
in the nucleus to form Lewy bodies (Kordower et al., 2011). Interest-
ingly, this study infected the rats with green ﬂuorescent protein (GFP)
as a control for the α-synuclein and found no transplanted cells ex-
pressing GFP; only α -synuclein transferred to the grafted cells
(Kordower et al., 2011). Fetal cells transplanted in PD patients were
found to last up to 16 years, but were found to develop α-synuclein-
positive Lewy bodies (Li et al., 2008). Grafting of fetal neuronal tissue
may therefore be limited and lead to failure in long-term transplanta-
tions.
It was also believed that these trials, using FVM, used a sub-optimal
amount of fetal tissue (Freed et al., 2001; Olanow et al., 2003). Al-
though these results are promising, they still pose concerns, including
the ethical and logistical challenges that are associated with grafting
FVM. There is a limited amount of fetal tissue to supply the amount of
patients with PD. In addition, these grafts did not contain a pure po-
pulation of DA cells, inducing dyskinesia. Therefore, re-focusing eﬀorts
on the utilization of NSCs, which oﬀer scalability and ease ethical
concerns (ﬁbroblast-derived), may hold more promise (Monni et al.,
2014; Choi et al., 2017;18.).
One paper from 2018 has investigated the secretome of human NSCs
in the 6-hydroxidopamine (6-OHDA) model of PD (Mendes-Pinheiro
et al., 2018). 6-OHDA, when injected, selectively destroys DA and
noradrenergic neurons and is therefore used as a model of PD. Human
NSCs were derived from the cortex of a 13-week old fetus that were
then serially subcultured (Baghbaderani et al., 2010). 6-OHDA was
unilaterally injected directly into the medial forebrain bundle of rats
and 5 weeks later the animals received hNSC transplants or hNSC se-
cretome (conditioned media) injected directly in the substantia nigra
pars compacta (SNpc) and into 4 striatum coordinates. 200,000 cells
were injected into the SNpc and 50,000 cells into each coordinate of the
striatum. hNSC conditioned medium was collected after 24 h on the
cells. Interestingly, motor performance of the animals, evaluated at 1, 4,
and 7 weeks after treatment, was signiﬁcantly improved in the group
treated with the hNSC conditioned media (CM) when compared with
both the untreated 6-OHDA group and hNSC-transplanted group
(Mendes-Pinheiro et al., 2018). Histological analyses of tyrosine hy-
droxylase positive neurons (DA neurons) 13 weeks after the lesion, in
both the SNpc and striatum, revealed an increase in cell survival in only
the hNSC CM group (Mendes-Pinheiro et al., 2018). Whether the hNSC
CM provided support to help promote neuronal survival or provide
regeneration after injury remains unanswered. Very little to no re-
covery in motor performance and TH neuron survival was seen in the
animals injected with hNSCs due to a very low rate of survival of cells
upon transplantation, which could be caused by a lack of im-
munosuppressive treatment. Other work using iPS-derived human NSCs
injected into the same rat PD model with immunosuppression showed
successful transplantation along with improvement in motor disability,
but did not investigate the secretome (Han et al., 2015).
In order to identify factors in the hNSC secretome the researchers
used a non-targeted proteomic analysis based on a combined mass
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spectrometry (MS) approach. They identiﬁed the well-known and ex-
pected neurotrophic factors GDNF and BDNF, which both support the
growth and survival of mature neurons in PD models (Fig. 1, Table 1)
(Baquet et al., 2005; Falk et al., 2010). Analyzing their proteomic data
they identiﬁed the majority of secreted proteins to be involved in the
cellular process and metabolic process. This includes the secretion of
antioxidant agents, such as TrxR1, Prdx1, and SOD enzymes, which
have been implicated in DA neuronal survival in PD models (Lee et al.,
2008; Arodin et al., 2014; Filograna et al., 2016). Overall, this is one of
the ﬁrst papers to directly demonstrate the neuroprotective and re-
generative qualities of the human NSC secretome in a rodent PD model
(Mendes-Pinheiro et al., 2018). Further investigation of the hNSC se-
cretome, and how it interacts with the environment, is imperative to
understand the complicated molecular pathways towards the clinical
utility of these cells.
2.5. Amyotrophic lateral sclerosis
Amyotrophic lateral sclerosis (ALS) is a fatal, adult onset neurode-
generative disease and the most common motor neuron disease in
adults (Cleveland and Rothstein, 2001). It is characterized by the se-
lective degeneration of both upper and lower motor neurons of the
primary motor cortex and brainstem and spinal cord, respectively
(Comley et al., 2015). 90–95% of ALS cases are sporadic, while the
remaining 20%, familial, are linked to diﬀering point mutations in the
Cu/Zn superoxide dismutase 1 gene (SOD1). Currently, only one drug
has been approved by the United States Food and Drug Administration
(FDA) for the treatment of ALS (Gurney et al., 1998), however it does
not stop the progression of the disease. Therefore, a critical gap in
available treatment options for ALS patients exists. Based upon the
pathology of disease involving the degeneration of motor neurons,
transplanted hNSCs ideally oﬀer the potential to provide trophic sup-
port as well as a cell replacement strategy.
Two recent studies have explored the therapeutic potential of
transplanted hNSCs in rodent models of ALS (Popescu et al., 2013;
Kondo et al., 2014). This ﬁrst study generated hNSCs from ﬁbroblast-
derived iPSCs. SOD1 rats, which harbor a mutation in the gene which
causes ALS-like pathology and symptoms, were injected with 105 hNSCs
in the ventral horns of the lumbar spinal cord (L4-L5) before the onset
of disease (3 months old) and maintained on immunosuppression
(Popescu et al., 2013). Mutations in the SOD1 gene account for 20% of
familial, genetic ALS and some sporadic ALS cases (Rosen et al., 1993).
Rodents with SOD1 mutations develop severe degeneration of motor
neurons, which leads to the progressive paralysis of the hindlimbs and
forelimbs, and eventually death (Browne and Abbott, 2016). 60 days
after transplantation the cells were found to diﬀerentiate into mature
neurons. This study provided evidence that iPSC-derived hNSCs can be
safely transplanted into rodents with ALS-like disease but is limited as
the transplants were performed before the onset of symptoms, and the
study did not analyze behavior or disease-induced pathology.
A similar study by Kondo et al. generated hNSCs from iPSCs and
diﬀerentiated these cells using leukemia inhibitory factory (LIF)/bone
morphogenic protein (MBP) signaling into what they termed hiPSC-
GRNPs (glial-rich neural progenitors). This protocol generated an en-
riched population of NESTIN positive neural stem cells (68.4% of the
population) and the other half positive for GFAP, which they remarked
to be immature astrocytes. Previous work demonstrated that rodent
astrocyte transplant into a mutant SOD1 rat promoted neural protection
so this study wanted to determine if an enriched glial population from
human cells could do the same (Xu et al., 2011). Along with im-
munosuppressive treatment they transplanted 40,000 hiPSC-GRNPs
bilaterally into the lumbar section of spinal cords of 90 day old mutant
SOD1 mice (Kondo et al., 2014). At this age the mice have already
started demonstrating disease progression (Kondo et al., 2014).
10–40 days after transplantation mice showed improvement in their
clinical motor score and lifespan was extended by 7.8% compared to
the non-transplanted SOD1 mutants. At the end stage of disease pro-
gression (140–170 days; 50–80 days post-transplant) the transplanted
hiPSC-GRNPs were found to survive in the lumbar spinal cord. Inter-
estingly compared to the ﬁrst paper discussed above (Popescu et al.,
2013) the majority of the transplanted cells diﬀerentiated into astro-
cytes, while diﬀerentiation into neurons or oligodendrocytes was low.
In order to investigate the factors secreted by the transplanted hiPSC-
GRNPs, human-speciﬁc primers were generated to assay mRNA in the
lumbar spinal cord tissue (Kondo et al., 2014). Only expression of
human VEGF was found increased in the host tissue, while injection of
the human cells increased endogenous expression of Vegf, Nt3, and Gdnf
(Fig. 1, Table 1). Furthermore, transplantation of hNSCs increased
phosphorylated AKT in the tissue, downstream of VEGF signaling,
which has previously been found to be important for cell survival in
ALS (Lunn et al., 2009). Although this study only showed modest
beneﬁts after human cell transplantation in mice with ALS-like disease,
it demonstrated that iPSC-derived GRNPs were safe and tolerated in
these mice.
These two studies oﬀer important insights in how hNSCs could be
used to treat ALS. Further work needs to be carried out to establish how
the secretome from transplanted hNSCs can promote neuroprotection,
and hopefully regeneration in this devastating disease. In addition, it is
critical to study in these rodent models how long-term transplantation
of these cells can aﬀect disease progression and the ideal time to
transplant these cells, whether it be before disease onset or during
disease progression.
2.6. Multiple sclerosis
Multiple Sclerosis (MS) is a chronic inﬂammatory demyelinating
disease of the CNS and is the most common inﬂammatory neurological
disease leading to non-traumatic disability in young adults worldwide
(Global, regional, and national burden of multiple sclerosis, 2016;
Wallin et al., 2019). MS is characterized by the formation of lesions
(demyelination of neurons) within the white matter of the brain and
spinal cord and the grey matter of the cortex, which leads to a gradual
accumulation of neurological disabilities (Bo et al., 2006; Calabrese
et al., 2013; Lublin et al., 2014). MS patients are broadly sub-divided
into two clinically distinct disease phenotypes: the relapsing-remitting
(RR) course, which is followed by a progressive phase (secondary
progressive), and the primary-progressive course, when progression
proceeds in the absence of preceding relapses or remissions (Lublin
et al., 2014). Demyelination in MS is in part caused by immune cells, T
cells, that gain entry into the CNS, recognize myelin as foreign and
destroy it. It is unknown how MS is caused, but the autoimmune
component of the disease has been hypothesized to be due to genetics
and environmental factors (ie. exposure to certain viruses, geographic
location) (Compston and Coles, 2008). A wide-range of disease-mod-
ifying therapies (DMTs) exist to slow the progression of the disease to
improve the quality of life for patients, but the disease still progresses
with no cure (Thompson et al., 2018). Despite the chronic demyelina-
tion that occurs throughout the natural history of the disease, the neural
tissue, seemingly, remains remarkably responsive to neurotrophic and
neurorestorative cues to initiate regeneration of the damaged tissue
(Franklin and Ffrench-Constant, 2008; Franklin and Ffrench-Constant,
2017). Therefore, transplantation of human NSCs in these patients may
oﬀer a restorative therapy through two potential mechanisms: altering
immune cell functioning and promoting neuroprotection and re-
generation.
The establishment of NSCs as a viable therapeutic option in the
treatment of MS has been well-established using rNSCs (Pluchino et al.,
2003; Peruzzotti-Jametti et al., 2018). For example, previous work has
indicated that transplanted rodent NSCs can secrete trophic factors such
as LIF, which can promote endogenous regeneration in rodent models
of MS, and can help buﬀer accumulated metabolites (Peruzzotti-Jametti
et al., 2018; Laterza et al., 2013). Given this foundation, recent
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evidence from hNSC transplants into rodent models of MS have further
strengthened this line of investigation (Peruzzotti-Jametti et al., 2018;
De Feo et al., 2017). Two recent studies have investigated the ability of
transplanted hNSCs to dampen the immune response via the secretion
of anti-inﬂammatory factors and induce a pro-regenerative environ-
ment in a viral model of MS (Chen et al., 2014; Plaisted et al., 2016).
Chen et al., generated hNSCs from a human embryonic stem cell line
and injected these cells into mice with a viral model of MS (Chen et al.,
2014). These mice were injected with a mouse strain of hepatitis virus
(JHMV) which results in an immune-mediated demyelination with
clinical and histologic similarities to MS. Destruction of myelin in this
model occurs due to the activation of T cells within the CNS caused by
the virus. Mice were infected intracranially and were transplanted with
2.5 × 105 hNSCs at T9 of the spinal cord 14 days after infection without
immunosuppression (Chen et al., 2014). Injection of the hNSCs resulted
in a reduction in the severity of the clinical disease that was sustained
out to 6 months after transplant. Interestingly, the hNSCs were found to
survive only for 1 week after transplantation, but were found to
dampen the presence of T cells along with activated macrophage/mi-
croglia and reduce severity of demyelination within the spinal cord
21 days after transplantation (Chen et al., 2014). Pathological and
clinical improvement was associated with an increase of regulatory T
cells (Tregs), which suppress the immune system, in the hNSC trans-
planted mice. The hNSC secretome was attributed to causing a long-
lasting response on the activated T cells, even though the transplanted
cells were found to be transient within the tissue (lasting only a week).
Conditioned media from the hNSCs revealed an increase in TGF-β1 and
TGF-β2, both anti-inﬂammatory cytokines (Fig. 1). Neutralizing anti-
bodies speciﬁc for TGF-β1 and TGF-β2 blocked the ability of hNSC
conditioned media to inhibit proliferation of activated T cells. This
study demonstrates how the secretome from hNSCs can have a long-
lasting eﬀect on the microenvironment by modulating activated im-
mune cells (Chen et al., 2014). Further understanding the impact of the
hNSC secretome in this model can help in the development of future
therapeutics for this disease.
In the same rodent model of MS, Plaisted and colleagues trans-
planted 250,000 hNSCs, derived from a human iPSC line, in the spinal
cord at T8-T9 14 days post injection without immunosuppressive
treatment (Plaisted et al., 2016). Just as the aforementioned study,
hNSCs were undetectable 8 days after transplantation, but at 21 days
post transplantation the animals displayed reduced demyelination. In
addition, they found restriction of inﬂammatory T cell migration into
the spinal cord with a concomitant increase in regulatory anti-in-
ﬂammatory T cells, associated with increased secretion of TGF-β1 and
TGF-β2 (Fig. 1) (Plaisted et al., 2016). These 2 studies provide a proof
of concept that hNSCs, derived from either embryonic stem cells for
iPSCs, are able to be transplanted safely and provide beneﬁcial eﬀects
via secretion of anti-inﬂammatory cytokines in this viral rodent model
of MS (Fig. 1) (Chen et al., 2014; Plaisted et al., 2016).
Despite these promising pre-clinical ﬁndings, caution must be used
regarding the source of hNSCs. Two recent studies have identiﬁed in-
herent defects and an altered secretome in hNSCs derived from iPSCs
generated from patients with primary progressive multiple sclerosis
arising from the development of a premature aging phenotype (Nicaise
et al., 2017; Nicaise et al., 2019). Therefore, extensive health screenings
must be carried out when developing human cells lines for the stable,
expandable use of hNSCs in the clinical setting. This work suggests that
autologous hNSCs may need to be genetically engineered to secrete
factors that are inﬂammatory as well as pro-regenerative before use in
the clinic or banks of healthy human cells could be generated for
clinical use. There also is some discrepancy in the pathology of the
relapsing form of MS compared to the progressive form, where pro-
inﬂammatory reactive T cells are much more prominent in the relapsing
form, while DMTs which target the inﬁltration of immune cells into the
CNS do not provide beneﬁt to progressive MS patients (Compston and
Coles, 2008). Therefore, hNSCs could be engineered to secrete factors
that beneﬁt pathology in relapsing MS (ie. TGF-β) as well as factors that
would beneﬁt regeneration (ie. LIF), which is stalled in progressive MS.
3. Therapeutic eﬃcacy of human NSC-secreted biologics for the
treatment of neurodegenerative diseases
The material presented thus far has shown the progress being made
in determining the viability of hNSC transplants as a therapeutic
strategy. One recurring theme from the recent data is the eﬀect of the
secretome from the transplanted hNSCs, which exerts a beneﬁcial and
therapeutic eﬀect through the secretion of potent immunomodulatory
and/or neurotrophic factors (Drago et al., 2013). This has led to an
alternate, but parallel, approach wherein signiﬁcant repair of the dis-
eased and damaged brain may be achieved via the non-invasive injec-
tion of the biologics secreted by hNSCs. Functional and biochemical
analysis of the rNSC secretome has revealed diverse and complex
properties of rNSC-secreted factors (Cossetti et al., 2014; Shoemaker
and Kornblum, 2016; Iraci et al., 2017; Stevanato et al., 2016; Ma et al.,
2019); some with therapeutic potential (Rong et al., 2019). This has
spurred an interest amongst a growing number of investigators to
identify similar properties of the hNSC secretome. Thus, we will focus
on recent literature identifying the beneﬁcial properties of hNSC-de-
rived extracellular vesicles (EVs) and conditioned medium (CM) as
treatments in pre-clinical models of neurodegenerative diseases.
3.1. Therapeutic potential of human NSC-extracellular vesicles and
conditioned media
Broadly, EVs are nano-sized independent signaling vehicles that
transport a deﬁned cargo, such as proteins, mRNA, and miRNA, to
target cells at local and distant sites (Tkach and Thery, 2016). Despite
intensive research into the biology of EVs, their complex biogenesis and
physiological role are only now being partially understood (Colombo
et al., 2014). An interesting facet of stem-cell EVs is the bidirectional
exchange of information between stem cells and target cells, which has
been shown to lead to the activation of regenerative programs (Camussi
et al., 2013). This remarkable feature of stem-cell EVs, their ability to
transfer functional material to other cells, is of particular importance
for hNSC-derived EVs in identifying and characterizing the relevant
mechanisms with the highest potential for treating complex neurode-
generative diseases (Vogel et al., 2018). Despite the glaring lack of
detailed characterization, growing interest into their potential as
mediators of cell–cell communication has generated a signiﬁcant in-
crease in attention from the scientiﬁc community. However, to date,
only a handful of studies have been conducted highlighting the promise
these small vesicles hold.
Two recent studies by Webb et al. using a rodent and porcine model
of stroke have highlighted beneﬁcial eﬀects of hNSC-EVs (Webb et al.,
2018; Webb et al., 2018). Using the MCAO animal model of stroke,
labeled hNSC-EVs were intravenously injected during the acute phase
of stroke to establish the targeting preference of hNSC-EVs. Imaging at
1 and 24 h after injection revealed eﬃcient targeting of hNSC-EVs to
the infarcted region of the brain (Webb et al., 2018). Additional ex vivo
imaging analysis found a signiﬁcant decrease in tissue loss in the hNSC-
EV treated animals with a concomitant improvement in motor function
and episodic memory. Analysis of blood using quantitative ﬂow cyto-
metry during the acute post-stroke phase revealed that hNSC-EVs pro-
moted the polarization of circulating macrophages from a pro-in-
ﬂammatory M1 phenotype to an anti-inﬂammatory M2 phenotype, as
well as increased the induction of Tregs leading to a down-regulation of
pro-inﬂammatory eﬀector Th17 cells (Webb et al., 2018). The ﬁndings
from these studies revealed the eﬃcacy of hNSC-EVs in providing
neuroprotecton, ameliorating the motor and memory impairments, and
dampening the inﬂammation common to this pre-clinical model. After
the exciting results generated from the rodent model, the same group
set out to investigate the potency of hNSC-EVs in a porcine model of
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stroke. Following permanent MCAO, hNSC-EVs were administered at
three time points during the acute phase. Consistent with the results
from the rodent model, stroked pigs had decreased lesion volume and
brain swelling, as well as increased ﬂuid movement through the brain
(Webb et al., 2018). hNSC-EV treatment was also found to preserve
white matter integrity in the brain when examined three months after
stroke. Furthermore, normal exploratory behavior, motor activity and
faster recovery was observed in pigs receiving the hNSC-EV injections
(Webb et al., 2018). Identiﬁcation of enhanced recovery in a larger
mammalian species is hugely exciting for the potential promise hNSC-
EVs hold in the development of clinically relevant therapies. Ad-
ditionally, results from the both the rodent and porcine studies had
similar outcomes when compared to the results generated from the
hNSCs transplantation studies.
Progress has also been made in the use of cell-free, conditioned
media (CM) from hNSCs for treatment in neurodegenerative diseases. A
study by Mendes-Pinheiro et al. found that injection of CM from hNSCs
into the 6-OHDA rodent model of PD had a neuroprotective eﬀect as
evidenced by a signiﬁcant increase in DA neuron survival, which was
outlined above (Mendes-Pinheiro et al., 2018). Despite the study being
limited in scope mechanistically, the results indicate that the hNSC
secretome in either isolation or conjunction with parallel treatments
(I.e. hNSC-EVs or hNSC transplants) could provide immediate and long-
term beneﬁt in patients with chronic neurodegenerative diseases.
Currently, it is unknown if hNSC-EVs/CM from diﬀerent or even
identical hNSC lines result in the same therapeutic proﬁle in treating all
neurodegenerative diseases. Further, characterization of EVs and CM
from the available clinical-grade hNSC lines must be carried out to
determine the precise proteomic map and assess functional outcomes in
other pre-clinical animal models of neurodegenerative diseases.
Expectations must be tempered as more investigative work is required
before these future therapies become a reality.
4. Human NSC transplantation in clinical trials
As described above, the pre-clinical animal models of disease have
established that exogenous hNSC transplants are a promising tool to
promote tissue regeneration in neurodegenerative diseases. Current
treatments options for these diseases are either non-existent or limited
and only eﬀective at ameliorating symptoms or delaying the progres-
sion. All known neurodegenerative diseases are currently incurable.
Thus, stem cells are an exciting ﬁeld that needs to be approached with
caution, with correctly designed clinical trials to determine the long-
term safety and eﬃcacy. The current pre-clinical animal models using
human NSCs are encouraging enough to justify Phase I and II clinical
trials in small patient cohorts.
Current clinical trials involving hNSCs are interested in establishing
the safety of transplantation, methodology of transplantation, the op-
timal number of cells to be transplanted, source of the cells, and the
collection of initial results detailing changes in disease pathology fol-
lowing transplantation (Table 2). Analyzing the eﬃcacy of stem cell
therapies is a challenging determination due to a variety of issues. First,
heterogeneity of cohorts is hard to avoid, especially the (i) type and
severity of the injury or disease, (ii) when transplantation will occur,
and (iii) the current DMTs of individual patients, among many other
variables. Secondly, the metrics assessed during follow-up need to be
designed to assess if some therapeutic beneﬁt has been reached, which
will vary from patient to patient depending on age, type of injury or
disease, and when intervention was initiated. Therefore, initial phase I
and II clinical trials for hNSC transplantation are critical to the future
use of these cells as therapeutics.
4.1. Spinal cord injury clinical trials
Current treatment options for spinal cord injury (SCI) include sur-
gical interventions and rehabilitative care, which does not provide a
cure for these patients. Phase I trials using hNSCs in SCI have found
spinal grafting of these cells to be safe and well-tolerated (Table 2).
These trials have been performed in patients with thoracic as well as
cervical injuries and have been done using allogenic (donor tissue)
hNSCs, with some lines approved by the FDA (Curtis et al., 2018). These
hNSCs have been derived from fetal spinal cord and expanded serially
in culture before transplantation. The initial phase I trials have de-
monstrated that injection in patients with chronic spinal cord injury can
be safely performed, with no identiﬁed adverse eﬀects 18–27 months
post-procedure (Curtis et al., 2018). A prominent phase II trial, that was
terminated because it did not reach required clinical eﬃcacy threshold,
reiterated the initial ﬁndings in patients with cervical spinal cord in-
jury. They found hNSC transplantation to be safe and well-tolerated
after a year in patients with chronic cervical SCI, and showed a trend in
increased motor performance in the patients, but did not achieve the
eﬃcacy needed (Levi et al., 2019). This phase II trial used a proprietary
stem cell line termed HuCNS-SCs that have been derived under GMP
conditions and are an allogenic line obtained from fetal brain tissue
(Tsukamoto et al., 2013). These initial studies in SCI have fallen short in
therapeutic expectations but have laid the groundwork to demonstrate
the safety of allogenic hNSC transplantation in the spinal cord. Further
studies are needed to conﬁrm potential beneﬁts, the proper dosage, the
best time to administer cells, the patient population that would beneﬁt
the most, and the best source to obtain the hNSCs. In addition, advances
in genetic engineering may provide a way to genetically alter hNSCs to
secrete speciﬁc factors known to support SCI regeneration.
4.2. Ischemic stroke clinical trials
A large number of studies in pre-clinical animal models has shown
an improvement in stroke recovery after hNSC transplantation (Huang
et al., 2014; Eckert et al., 2015). Most of these studies have shown that
these transplanted cells not only replace damaged cells, but also pro-
vide trophic support that improves the damaged environment creating
a path towards regeneration. The company ReNeuron Limited has in-
itiated both phase I and II clinical trials using allogenic hNSCs derived
from fetal tissue to transplant in the putamen region of stroke patients.
Their phase I clinical trial reported no cell-related adverse eﬀects a year
after transplantation with claims of mild improvements observed in
neurological function (Kalladka et al., 2016). Currently, a phase II trial
is underway to evaluate the clinical beneﬁt of NSC transplants in pa-
tients after stroke (Table 2). A second phase I trial out of China has
demonstrated safe transplantation of NSCs in the peri-infarct area of
ischemic stroke patients, using allogenic hNSCs from fetal tissue. Re-
ported ﬁndings are similar to those from the ReNeuron Limited trial,
transplants were well-tolerated with no adverse immune reactions.
Even though this clinical trial was not designed to evaluate eﬃcacy, the
authors claim that preliminary clinical beneﬁts were identiﬁed by ob-
serving new tissue at the site of injection 24 months after using MRI,
but no conclusions can be made on the eﬃcacy of this treatment (Zhang
et al., 2019). Extensive work is still required before the implementation
of hNSCs into the clinic for stroke patients, and the results of the current
phase II trial may provide an understanding on their eﬃcacy in treating
patients.
4.3. Alzheimer’s disease clinical trials
Based on growing interest, and the continuation of safe and well-
tolerated phase I clinical trials using hNSCs, stem cell therapies may be
a new hope for Alzheimer’s disease patients. In animal models, trans-
planted hNSCs provide a functional graft, but it is still unknown whe-
ther they would be well tolerated and integrated in the host AD brain
(Kwak et al., 2018). Preclinical studies using AD animal models have
provided promising results, but human clinical trials are still in their
infancy. There are still many unanswered questions associated with this
disease, and further research will provide a better understanding for
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how targeted hNSC therapy could provide regeneration and neuropro-
tection. Thus far there have been no reported clinical trials in-
vestigating the safety and tolerability of hNSCs in AD patients.
4.4. Parkinson’s disease clinical trials
In the ﬁrst phase I clinical trial of its kind, the International Stem
Cell Corporation has received approval to inject a new human parthe-
nogenetic derived NSC line (ISC-hpNSC) in patients with Parkinson’s
disease, which have been cleared by the FDA for clinical use.
Parthenogenetic cells are derived from the chemical activation of un-
fertilized oocytes which generates ES-like cells that can be diﬀer-
entiated in culture (Revazova et al., 2007). This bypasses the ethical
concerns associated with fetal tissue. These cells will be grafted next to
the caudate nucleus, putamen, and substantia nigra and are primed to
be used for providing trophic support and cellular replacement, in
contrast to just injecting dopaminergic neurons. Phase I trials using
hNSCs in PD have yet to generate any safety data, but these cells were
found to engraft safely in a nonhuman primate model of PD and based
on previous clinical trials with hNSCs they are expected to be safe and
well-tolerated (Table 2) (Gonzalez et al., 2016).
4.5. Amyotrophic lateral sclerosis clinical trials
ALS is currently incurable and only two drugs have been approved,
having only modest beneﬁts (Mazzini et al., 2019). Initial phase I
clinical trials using fetal hNSCs, expanded in vitro, and transplanted into
the lumbar spinal cord were found to be safe and well-tolerated
(Goutman et al., 2018). Recently, results from a follow up phase I trial
have been published (Table 2). This study had a larger patient cohort
and used the same line of fetal hNSCs transplanted into the lumbar and
cervical spinal cord. After surgery these patients were followed up
monthly for a year, and then every 3 months until death. This study
determined that the concentration of hNSCs transplanted was safe and
well-tolerated, with no immunological reactions. Even though this
study was not designed to determine the eﬃcacy of the treatment, it
was still a secondary endpoint. Overall the transplantation was not
found to extend life, however 50% of the patients reported a transient
functional improvement after surgery, but these results are diﬃcult to
interpret due to a lack of a placebo group within the experimental
design (Mazzini et al., 2019). These preliminary results have provided
suﬃcient promise to continue towards phase II trials, which are cur-
rently in preparation by the same group (Mazzini et al., 2019).
4.6. Multiple sclerosis clinical trials
hNSC transplantation for MS patients is a promising way to provide
neuroprotection through remyelination and dampening of the immune
response. Patients with the progressive form of MS have very limited
therapeutic opportunities, therefore hNSC therapy has been primarily
targeted towards this population as it may oﬀer the opportunity to slow
down disease progression. As reviewed above, in rodent models hNSCs
can have peripheral immunomodulatory eﬀects and indirectly inﬂuence
remyelination. Currently hNSC clinical trials are limited, but a recent
interest of their eﬃcacy in progressive MS has started. A phase I clinical
trial, which used autologous mesenchymal stem cell (MSC)-NSCs ad-
ministered intrathecally in progressive MS patients established their
safety and tolerability after 24 months (Harris et al., 2018). Being a
phase I study, it was not designed to assay eﬃcacy, but authors found a
positive improvement of disability in 40% of the patients treated, which
they attributed to the multiple injections of human MSC-NSCs. These
claims should be taken with caution, as the study did not have a placebo
group, but warrants a larger phase II study in the future. This work has
initiated a phase II trial (Table 2) using autologous human MSC-NSCs in
a larger progressive MS cohort with the addition of a placebo group in
order to determine their eﬃcacy in promoting neuroprotection. In
addition, two other phase I clinical trials using allogenic fetal-derived
hNSCs have recently started in order to determine the safety proﬁle in
both intrathecal and intracerebroventricular transplantation. Current
work suggests a dysfunction in the endogenous oligodendrocyte pro-
genitor population, which facilitates the need for exogenous cell
therapy to provide protective immunomodulatory properties and sti-
mulate regeneration (Jakel et al., 2019; Schirmer et al., 2019). Despite
the progress made, further work is required to understand disease
processes and to verify safety and eﬃcacy before the optimal hNSC
therapy can be generated and targeted for the clinic.
5. Conclusions
There are still several questions that need to be addressed for the
clinical translation of hNSC therapies, such as the optimal cell source
and the overall long-term safety. The current inﬂux of phase I clinical
trials using NSCs will eventually give an answer on the long-term
safety, especially on the concern of tumor formation and immuno-re-
jection. The generation of induced pluripotent stem cells (iPSCs) from
patient cells has portended the use of autologous transplants, which
would then circumvent immunological incompatibility as well as the
ethics associated with fetal tissue. The diﬀerentiation of hiPSCs into
hNSCs has become a well-known method, but the possibility of having a
few remaining pluripotent cells becomes an issue when transplanting
into patients. The direct conversion of human somatic cells into hNSCs
bypasses the pluripotent state, making them an ideal candidate for
transplantation (Thier et al., 2012). This methodology can be used to
overcome histocompatibility through the use of autologous cells with
negligible teratogenic potential but has yet to make it to clinical trial.
The appropriate source of NSCs for transplantation may be diﬀerent
depending on disease. For example, autologous-derived hNSCs from
certain diseases may harbor genetic and epigenetic mutations, therefore
an allogenic source would provide greater beneﬁt, but may cause his-
tocompatibility issues. Overall, the continuation in basic research and
phase I and II clinical trials using hNSCs will provide a more thorough
understanding of the biological mechanisms underpinning their bene-
ﬁcial impact in neurodegenerative diseases.
Knowing how hNSCs repair and promote regeneration, whether it
be through trophic modulation, cellular replacement, or both, will
allow for a more targeted cellular therapy in the future.
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